Join Growin Stock Community!

Pfizer inc(PFE.US AI Earnings Summary)

US StockHealthcare
No presentation for PFE

PFE AI Earnings Summary (In-Depth)

Last updated: 2026-11-03 (US time)

2026 Q3

Core Highlights

  • Management Expectations: Both revenue and earnings for this quarter exceeded management's internal expectations. Highlights included $16.6B in revenue and adjusted EPS of $0.87, primarily driven by 32% operational growth from new launches and acquired products.
  • Vs. Previous Guidance: Last quarter's guidance was on a full-year basis (full-year revenue of $60.5B–$62.5B, full-year adjusted EPS of $2.80–$3.00). This quarter's actual figures ($16.6B revenue, $0.87 adjusted EPS) are not directly comparable to full-year guidance. CFO Cécile Guegan explicitly stated that performance this quarter was better than management's expectations.
  • In One Sentence: PFIZER INC (PFE) raised its full-year guidance driven by strong momentum in non-COVID products and acquired assets, highlighting commercial execution and cost control effectiveness.

Quarterly Highlights

Driven by the dual engines of non-COVID products and the launch/acquisition portfolio, management reported that both revenue and adjusted EPS for the quarter exceeded their expectations.

  1. Steady Growth in Non-COVID Products, Quarterly Revenue Exceeds Management Expectations: 2026 Q3 total revenue was $16.6B, with non-COVID products growing 7% at constant exchange rates (CER), contributed by ELIQUIS, the VYNDAQEL family, NURTEC, and LORBRENA. CFO Cécile Guegan stated that quarterly revenue was "better than management's expectations," leading to a $1.5B increase in the full-year revenue guidance midpoint to $62B–$64B.

  2. Accelerated Growth in Launch and Acquisition Portfolio, Seagen Assets Shine: Launched and acquired products contributed $3.8B this quarter, growing 32% CER. The Seagen legacy portfolio grew 39% YoY in the U.S., with PADCEV up $255M, NURTEC up $135M (33% CER growth), and LORBRENA up $114M. CEO Albert Bourla noted that oncology commercial coverage depth has significantly improved since the Seagen integration.

  3. Adjusted EPS Exceeds Management Expectations, Gross Margin Remains High: 2026 Q3 adjusted diluted EPS was $0.87, which management stated was above their expectations even after absorbing a $0.10 per share charge from the Innovent transaction. Adjusted gross margin reached 77%, and adjusted cost of goods sold as a percentage of revenue fell from 23.9% to 23.2% (down 0.7 percentage points), reflecting product mix improvement and continuous cost control.

  4. Full-Year Adjusted EPS Guidance Raised and Narrowed: Full-year adjusted diluted EPS guidance was raised and narrowed from $2.80–$3.00 to $2.95–$3.05, representing a $0.10 increase at the midpoint while absorbing the $0.10 per share impact from the Innovent deal. Management reaffirmed the full-year adjusted gross margin expectation of approximately 73%–77%.

  5. Cost Alignment Program Ahead of Schedule, Phase 2 Savings Target Launched: The first phase of the cost improvement program (targeting $7.2B in net savings) is expected to complete nearly all goals by the end of 2026. Phase 2 has been launched, aiming for an additional $2.5B in net savings from 2027 to 2029, covering SI&A and manufacturing costs to buffer margin pressure during the Loss of Exclusivity (LOE) transition period.

  6. ELREXFIO Phase 3 Trial Double Positive Readout, Increased Confidence in Multiple Myeloma Pipeline: The MagnetisMM-32 trial showed that ELREXFIO monotherapy achieved statistically significant and clinically meaningful improvements in progression-free survival (PFS) compared to three standard-of-care treatments. At the interim analysis, over 75% of patients had not progressed or died, with an 18-month PFS rate of approximately 68%. Chief Scientific Officer Chris Boshoff noted that two positive Phase 3 results strengthen confidence in moving ELREXFIO into earlier lines of treatment.

  7. Obesity Pipeline Progresses, Berobenatide Phase 3 Program Fully Underway: In 2026, the company plans to advance 10 active or planned Phase 3 trials for berobenatide, including a study evaluating a switch from weekly therapy to a monthly GLP-1 peptide. The Phase 2b trial for the amylin combination program (SOLIS-1) has completed enrollment, with efficacy data expected in H2 2027. Management reaffirmed the first berobenatide approval goal for 2028.

  8. Robust Cash Flow, Disciplined Capital Allocation: Cumulative operating cash flow for the first three quarters of 2026 was approximately $8.8B. During this period, $9.2B was invested in internal and external R&D, and $7.3B was returned to shareholders via quarterly dividends. Leverage stood at 2.6x at quarter-end, slightly below the 2026 target of 2.7x. After the Innovent transaction, remaining business development (BD) capacity is approximately $6B.

Sign up for free!

You can sign up for free or Log In to read more information!

Free In-Depth for popular US stocks:

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer